Kenneth Harrison

Kenneth Harrison has served as a member of their board of directors since June 2021. Dr. Harrison is a Partner at Novo Ventures (U.S.) Inc., which provides consulting services to Novo Holdings A/S, an investment firm focused on life sciences and finance, and has been employed by Novo Ventures (U.S.) Inc. since November 2015. Prior to joining Novo, Dr. Harrison served as Senior Market Planning Manager at Genentech, USA Inc., a private biotechnology company, from 2013 to 2015, where he helped guide strategic decision-making for the Ophthalmology and HER2 franchises.

Dr. Harrison previously worked as a management consultant at L.E.K. Consulting LLC, a consulting firm, and as the Entrepreneurship Program Manager at QB3, a nonprofit research and technology commercialization institute, and Mission Bay Capital LLC, an early stage life science venture capital firm, where he helped create new programs to launch and support life sciences companies in the Bay Area. Dr. Harrison studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes, received a PhD in pharmacology from Yale University, and received a BS in molecular biology from Texas Tech University, where he was a Howard Hughes Medical Institute undergraduate research fellow.